- In September Professor Radford appeared as a guest speaker at the Global Cardio-Oncology Summit 2017 in London where he delivered a talk on the long term cardiovascular outcomes in survivors of Hodgkin lymphoma.
- In July we became the first site in the world to open the new CTCL chart review study. This study looks at real-world treatment patterns and outcomes in relapsed/refractory cutaneous T-cell lymphoma (CTCL).
- Professor Radford appeared on North West Tonight in July for an interview with patient Michael Prestidge who has had a dramatic response to the ADCT-402 trial after failing to adequately respond to many previous treatments including 4 other clinical trials. Michael's story was featured in local newspapers and he appeared in a BBC Radio 5 Live interview.
- We give a warm welcome to our new research nurse Chiara Dallatorre who started on the team in June 2017. Chiara is an experienced haematology nurse who has previously worked for Blackpool Victoria Hospital and we are sure she will make a great addition to our research team.
- Professor John Radford has recently been invited to join the editorial board of the AOL (Annals of Lymphoma) which is a rising high quality electronic journal, openly distributed worldwide relating to lymphoma research.
- In January Professor Radford and Dr Gibb were named as lead authors on a Pfizer abstract to be presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland in June this year.
- We are very happy to announce that on the 17th November our team were named winners of Research Team Of The Year at the Greater Manchester Clinical Research Awards 2016!
- On the 22nd of October 2016 The BREVITY trial along with our other projects ADAPT and BARD were presented at ISHL (International Symposium of Hodgkin lymphoma) in Cologne by Professor Radford and Dr Adam Gibb.
- In November our team was the 1st recruiter in the UK for the SGN35.023 trial. This study looks at comparing treatment with the combination of rituximab and bendamustine chemotherapy against the combination of rituximab and bendamustine with added brentuximab.
- The Lymphoma Group were the 1st recruiter in the world for the BI 1206 CRUK clinical trial. BI 1206 is a type of biological therapy called an antibody. It works by recognising and attaching to a particular protein called CD32b. This protein is found on some cancer cells in some types of lymphoma and leukaemia. Laboratory studies show that by blocking the CD32b protein BI 1206 could stop cancer cells from growing and dividing. Researchers want to find out if BI 1206 can help people with B cell non Hodgkin lymphoma and chronic lymphocytic leukaemia (CLL).
- Our team has now been re-designated as a Bloodwise TAP (Trials Acceleration Programme) Centre, making us 1 of 13 centres nationally.
- Our clinical research nurse Andrea Whitmore successfully completed a skin biopsy course and will now be carrying out biopsies for our lymphoma patients when required. This will be highly beneficial as it prevents the need to use other services, reduces patient waiting times and will be more convenient to our patients overall. Well done Andrea!
- The Lymphoma Group were the UK's top recruiter for the Polatuzumab Vedotin trial (GO29365). This study was looking at Polatuzumab Vedotin in combination with Bendamustine and Rituximab or Obinutuzumab.
- The Lymphoma Group were the UK's first recruiter and second global recruiter for the JAVELIN Hodgkin lymphoma trial which is a study looking at Avelumab in patients with previously treated advanced stage Hodgkin lymphoma.